Individuals’ susceptibility to genetic and epigenetic factors may be responsible for the transformation of episodic migraine to chronic migraine in some patients, according to a new review published in The Journal of Headache and Pain.
Individuals’ susceptibility to genetic and epigenetic factors may be responsible for the transformation of episodic migraine to chronic migraine in some patients, according to a new review published in The Journal of Headache and Pain.
Migraine is a life span disorder and affects about 15% of the general population. According to the World Health Organization, migraine is the most prevalent, disabling, and long-term neurological condition when accounting for years lost due to disability. The review aimed to discuss what possible mechanisms are behind a largely unknown evolutive process.
Genetic factors may determine how susceptible a person is to a migraine attack while environmental factors may trigger an attack, according to the review. Genome-wide association studies, which test for differences in allele frequencies of single nucleotide polymorphisms over the genome in migraine patients and controls, found that multigenetic variants, as opposed to a single gene, can contribute to migraine susceptibility.
Epigenetics, or “modification of gene expression without altering the underlying DNA sequence” may also play a factor. However, epigenetics is a new area of research and only a handful of studies have been conducted on patients with migraine. Some studies found cortical structural changes in patients but results are unclear as to whether cortical thinning or thickening took place in the brain. Structural changes like gray matter changes may also be a cause.
Many factors can trigger a migraine attack, and stess and lack of sleep “are probably the most common triggers,” according to the review. The researchers divide migraines into a preliminary phase, a pain phase, and a postdrome phase, as migraine attacks tend to follow patterns. An aura phase will occur in around 15-20% of patients. During the postdrome phase, about 80% of patients report one non-headache symptom.
“To date, studies failed to shed any light on how such genetic alterations may be responsible for migraine pathophysiology or any evolutive mechanism” the review states. “On the other hand, anatomical changes in the brain of a migraine patient exist even from early childhood, but they do not seem to have any functional consequences.”
Migraine is an evolutive condition, even in its episodic form. According to authors, different mechanisms such as cortical excitability in the aura phase and hypothalamic alterations in the premonitory phase are involved in the evolutive process of the attack.
“The causality dilemma of whether such changes are responsible for how migraine evolves, or whether migraine mechanisms drive these anatomic changes, remains to be answered” the review states.
Reference
Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition [published online December 23, 2019]. J Headache Pain. doi: 10.1186/s10194-019-1066-0.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen